샘플 요청 목록

 카트 문의
시장보고서
상품코드
1941457

종양 절제 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 치료별, 용도별, 지역별, 부문별 예측(2026-2033년)

Tumor Ablation Market Size, Share & Trends Analysis Report By Technology, By Treatment, By Application, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 170 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

종양 절제 시장 요약

세계의 종양 절제 시장 규모는 2025년에 21억 4,000만 달러로 추정되며, 2033년까지 61억 달러에 달할 것으로 예측됩니다.

2026-2033년 연평균 복합 성장률(CAGR) 14.1%를 나타낼 것으로 예측됩니다. 절제술은 종양을 절제하지 않고 파괴하는 치료법입니다.

이 기술은 작은 종양이 여러개 있는 환자나 수술이 불가능한 경우에 유용하게 사용할 수 있습니다. 또한 이러한 치료를 받는 환자들은 입원할 필요가 없기 때문에 개인들의 절제 시스템 채택률이 높아지고 있습니다. 유방암, 대장암, 전립선암, 폐암 등 다양한 유형의 암 유병률 증가는 신장, 연부조직, 간, 뼈의 종양 치료를 위한 절제 기술에 대한 수요를 촉진할 것으로 예측됩니다. 암은 주요 사망 원인 중 하나이기 때문에 전 세계 의료 문제로 인식되고 있습니다. 예를 들어 미국 국립보건통계센터에 따르면 2023년 미국에서는 약 195만 8,310건의 신규 암 발생과 60만 9,820명의 암 사망자가 발생할 것으로 추정됩니다.

또한 아시아태평양, 특히 일본, 인도, 중국 등 미개발 기회가 큰 국가들의 노인 인구 증가는 예측 기간 중 시장 확대를 견인할 것으로 예측됩니다. 또한 현재 미국에서는 노인(65세 이상)이 일반 인구 중 가장 빠르게 증가하고 있는 그룹입니다. 미국 인구조사국의 2017년 전국 인구 추계에 따르면 2060년까지 미국 시민 4명 중 1명은 노인이 될 것으로 예측됩니다. 이 추정에 따르면 2030년까지 베이비붐 세대가 모두 65세 이상이 될 것으로 예상하고 있습니다.

절제 장치의 기술 발전으로 정확성, 휴대성, 비용 효율성이 향상됨에 따라 시장 관계자들은 첨단 장비의 지속적인 개발 및 개선을 추진하고 있습니다. 비가역적 전기 천공법, 고밀도 집속 초음파(HIFU), 냉동 절제술, 영상 유도 장치 등이 시장의 기술 발전의 주요 예입니다. 기존 기술의 개선과 새로운 절제 기술의 도입으로 다른 장기의 더 크고 복잡한 종양의 치료가 가능해졌습니다. 또한 시술 중 이미징 기술의 발전은 치료의 질적 향상과 합병증 최소화를 목표로 하고 있습니다. 따라서 시술 중 영상 기술의 발전은 치료 준비를 개선하고 치료 중 절제 부위를 정확하게 평가할 수 있게 해줍니다.

여러 시장 진입 업체들은 시장에서의 확고한 지위를 유지하기 위해 새로운 절제 장치를 개발 및 출시하기 위해 노력하고 있으며, 여러 절제 시스템이 미국 FDA의 규제 승인을 받고 있습니다. 예를 들어 2022년 9월 Stryker의 발표에 따르면 자사의 뼈 종양 절제 시스템 'OptaBlate'가 미국 FDA로부터 510(k) 승인을 받았다고 합니다. 옵타블레이트 기술을 포트폴리오에 추가함으로써 인터벤션 척추(IVS) 제품군은 전이성 척추 골절에 대한 종합적인 치료 옵션을 제공할 수 있게 되었으며, 척추 강화술 및 RFA(Radiofrequency Ablation) 분야의 핵심 역량을 더욱 강화할 수 있게 되었습니다.

또한 저침습 수술은 환자의 부담이 적고 침습적 수술에 비해 회복이 빠르다는 점에서 그 수요가 증가하고 있습니다. 종양 절제 수술은 절개가 필요 없기 때문에 비침습적이라고 할 수 있습니다. 최소침습수술에 대한 수요를 촉진하는 또 다른 요인은 개복수술의 감염 위험입니다. 비침습적 방법은 시간과 의료비를 절약하여 입원 기간을 단축시킵니다. 또한 고령화 인구 증가와 비만의 확산은 시장 성장을 가속할 것으로 예측됩니다. 세계보건기구(WHO)에 따르면 2030년까지 세계 인구 6명 중 1명이 60세 이상이 될 것으로 예측됩니다. 이러한 요인들이 복합적으로 작용하여 종양 절제술 시장의 성장에 기여하고 있습니다.

자주 묻는 질문

  • 종양 절제 시장 규모는 어떻게 예측되나요?
  • 종양 절제술의 주요 이점은 무엇인가요?
  • 종양 절제 시장의 성장 요인은 무엇인가요?
  • 종양 절제술의 기술 발전은 어떤 방향으로 진행되고 있나요?
  • 종양 절제 시장의 주요 기업은 어디인가요?

목차

제1장 조사 방법과 범위

제2장 개요

제3장 종양 절제 시장 변수, 동향, 범위

제4장 종양 절제 시장 : 기술별 추정·동향 분석

제5장 종양 절제 시장 : 치료별 추정·동향 분석

제6장 종양 절제 시장 : 용도별 추정·동향 분석

제7장 종양 절제 시장 : 지역별 추정·동향 분석

제8장 경쟁 구도

KSA 26.03.12

Tumor Ablation Market Summary

The global tumor ablation market size was estimated at USD 2.14 billion in 2025 and is projected to reach USD 6.10 billion by 2033, growing at a CAGR of 14.1% from 2026 to 2033. Ablation is a treatment that destroys tumors without removing them.

This technique is useful in patients with a few small tumors and, at times, when surgery is not an option. Moreover, patients getting this type of treatment do not need to stay in the hospital, thereby increasing the adoption rate of ablation systems among individuals. Rise in the prevalence of various types of cancers, such as those of breast, colon, prostate, and lung, is anticipated to boost the demand for ablation technologies for the treatment of tumors in the kidney, soft tissue, liver, and bone. Cancer is considered a universal healthcare problem, as it is one of the leading causes of death. For instance, according to the National Center for Health Statistics, in 2023, almost 1,958,310 new cancer cases and 609,820 cancer deaths were estimated in the U.S.

Moreover, the increase in the geriatric population in the Asia Pacific region, especially in countries with large untapped opportunities, such as Japan, India, and China, is expected to drive the market over the forecast period. Furthermore, elderly people (aged >=65) are currently the fastest-growing group among the general population in the U.S. According to the U.S. Census Bureau's 2017 National Population Projections, by 2060, nearly one in four U.S. citizens is likely to be an older adult. According to the same source, by 2030, all baby boomers are expected to be older than 65.

Technological advancements in ablation devices have facilitated accuracy, portability, and cost-effectiveness, encouraging market players to launch and improve advanced devices constantly. Irreversible electroporation, High-intensity focused ultrasound (HIFU), cryoablation, and image-guided equipment are some of the major examples of technological advancements in the market. Alterations in existing technologies and the introduction of novel ablation techniques make it possible to treat larger & more complex tumors in other organs. Furthermore, developments in intraprocedural imaging aim to increase treatment quality and minimize complications. Hence, advancements in intraprocedural imaging have improved treatment preparation and offer accurate assessment of the ablation zone during treatment.

Several market participants aim to develop and launch novel ablation devices to maintain strong positions in the market, and several ablation systems are receiving regulatory approval from the U.S. FDA. For instance, in September 2022, the U.S. FDA granted 510(k) clearance to Stryker's OptaBlate bone tumor ablation system (OptaBlate), according to a statement from Stryker. With the inclusion of OptaBlate technology in its portfolio, company's Interventional Spine (IVS) portfolio now offers a full range of therapeutic options for metastatic vertebral body fractures, expanding on its core capabilities in vertebral augmentation and Radiofrequency Ablation (RFA).

Moreover, demand for minimally invasive procedures is increasing as they result in lower trauma to the patient and facilitate quicker recovery compared to invasive procedures. No incision is required in a tumor ablation procedure, making it noninvasive. Another factor driving the demand for minimally invasive surgeries is the risk of infection during open surgeries. Noninvasive methods decrease hospital stays by saving time and medical costs. Furthermore, a rise in the aging population and the prevalence of obesity is expected to boost market growth. According to the World Health Organization (WHO), 1 in 6 people worldwide will be 60 years or above by 2030. Thes efcators are collectively contributing to the growth of tumor ablation market.

Global Tumor Ablation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the global tumor ablation market report based on technology, treatment, application, and region:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Radiofrequency Ablation
  • Microwave Ablation
  • Cryoablation
  • Irreversible Electroporation Ablation
  • HIFU
  • Other Ablation Technologies
  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Surgical Ablation
  • Laparoscopic Ablation
  • Percutaneous Ablation
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Kidney Cancer
  • Liver Cancer
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Other Cancer
  • Region Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Norway
    • Denmark
    • Sweden
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • Thailand
    • Australia
    • India
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Treatment
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Treatment outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Tumor Ablation Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Tumor Ablation Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Tumor Ablation Market: Technology Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Tumor Ablation Market: Technology Movement Analysis
  • 4.3. Tumor Ablation Market by Technology Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5. Radiofrequency Ablation
    • 4.5.1. Radiofrequency Ablation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Microwave Ablation
    • 4.6.1. Microwave Ablation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Cryoablation
    • 4.7.1. Cryoablation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Irreversible Electroporation Ablation
    • 4.8.1. Irreversible Electroporation Ablation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.9. HIFU
    • 4.9.1. HIFU Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.10. Other Ablation Technologies
    • 4.10.1. Other Ablation Technologies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Tumor Ablation Market: Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Tumor Ablation Market: Treatment Movement Analysis
  • 5.3. Tumor Ablation Market by Treatment Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Surgical Ablation
    • 5.5.1. Surgical Ablation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Laparoscopic Ablation
    • 5.6.1. Laparoscopic Ablation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Percutaneous Ablation
    • 5.7.1. Percutaneous Ablation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Tumor Ablation Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Tumor Ablation Market: Application Movement Analysis
  • 6.3. Tumor Ablation Market by Application Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Kidney Cancer
    • 6.5.1. Kidney Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Liver Cancer
    • 6.6.1. Liver Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Breast Cancer
    • 6.7.1. Breast Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Lung Cancer
    • 6.8.1. Lung Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Prostate Cancer
    • 6.9.1. Prostate Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Other Cancer
    • 6.10.1. Other Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Tumor Ablation Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Regional Tumor Ablation Market Movement Analysis
  • 7.3. Tumor Ablation Market: Regional Estimates & Trend Analysis by Technology & Application
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. North America
    • 7.5.1. North America Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. U.S.
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement scenario
      • 7.5.2.5. U.S. Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement scenario
      • 7.5.3.5. Canada Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement scenario
      • 7.5.4.5. Mexico Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Europe
    • 7.5.6. Europe Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. UK
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement scenario
      • 7.5.7.5. UK Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Germany
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement scenario
      • 7.5.8.5. Germany Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. France
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement scenario
      • 7.5.9.5. France Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.10. Italy
      • 7.5.10.1. Key Country Dynamics
      • 7.5.10.2. Competitive Scenario
      • 7.5.10.3. Regulatory Framework
      • 7.5.10.4. Reimbursement scenario
      • 7.5.10.5. Italy Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.11. Spain
      • 7.5.11.1. Key Country Dynamics
      • 7.5.11.2. Competitive Scenario
      • 7.5.11.3. Regulatory Framework
      • 7.5.11.4. Reimbursement scenario
      • 7.5.11.5. Spain Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.12. Denmark
      • 7.5.12.1. Key Country Dynamics
      • 7.5.12.2. Competitive Scenario
      • 7.5.12.3. Regulatory Framework
      • 7.5.12.4. Reimbursement scenario
      • 7.5.12.5. Denmark Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.13. Sweden
      • 7.5.13.1. Key Country Dynamics
      • 7.5.13.2. Competitive Scenario
      • 7.5.13.3. Regulatory Framework
      • 7.5.13.4. Reimbursement scenario
      • 7.5.13.5. Sweden Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.14. Norway
      • 7.5.14.1. Key Country Dynamics
      • 7.5.14.2. Competitive Scenario
      • 7.5.14.3. Regulatory Framework
      • 7.5.14.4. Reimbursement scenario
      • 7.5.14.5. Norway Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement scenario
      • 7.6.2.5. Japan Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement scenario
      • 7.6.3.5. China Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement scenario
      • 7.6.4.5. India Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement scenario
      • 7.6.5.5. South Korea Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement scenario
      • 7.6.6.5. Australia Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement scenario
      • 7.6.7.5. Thailand Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement scenario
      • 7.7.2.5. Brazil Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement scenario
      • 7.7.3.5. Argentina Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East & Africa
    • 7.8.1. Middle East & Africa Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement scenario
      • 7.8.2.5. South Africa Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement scenario
      • 7.8.3.5. Saudi Arabia Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement scenario
      • 7.8.4.5. UAE Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement scenario
      • 7.8.5.5. Kuwait Tumor Ablation Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Key Company Profiles
    • 8.2.1. Medtronic plc
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Product Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. Boston Scientific Corporation
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Product Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. Johnson & Johnson Service Inc. (Ethicon, Inc.)
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Product Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. AngioDynamics
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Product Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. Bioventus Inc. (Misonix Inc.)
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Product Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. EDAP TMS
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Product Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. Chongqing Haifu Medical Technology Co., Ltd
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Product Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. Mermaid Medical
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Product Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. HealthTronics, Inc.
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Product Benchmarking
      • 8.2.9.4. Strategic Initiatives
    • 8.2.10. H.S. Hospital Service S.p.A.
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Performance
      • 8.2.10.3. Product Benchmarking
      • 8.2.10.4. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제